Overview / Abstract: |
The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications has become an important option for treating patients with type 2 diabetes mellitus (T2D). Cardiovascular outcome trials also show that selected GLP-1RAs exert beneficial cardiovascular benefits in patients with and without T2D. In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and their own experience, cardiologist Jorge Plutzy, MD, and endocrinologist Helena Rodbard, MD, navigate through a series of ‘clinical questions’ to inform regarding the clinical pharmacology of the GLP-1RAs and their evidence-based role in cardiovascular risk reduction, particularly in patients with secondary atherosclerotic cardiovascular disease. The faculty also provide recommendations to optimize the use of GLP-1RAs as a class, as well as individually, including strategies to mitigate gastrointestinal adverse events and address patient concerns. In closing, Dr. Plutzky underscores the essential role of cardiologists in diabetes care, advocating for a collaborative, interprofessional team approach to optimize the health of patients with chronic coronary disease. |
Expiration |
Feb 28, 2025 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
1.25 |
Accreditation |
ACCME; ANCC; CA-BRN, AAPA |
Presenters / Authors / Faculty |
Jorge Plutzky, MD Helena W. Rodbard, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Novo Nordisk. |
Keywords / Search Terms |
Annenberg Center for Health Sciences at Eisenhower Free CE CME |